Rare Cell Isolation Technique Improved
|
By LabMedica International staff writers Posted on 06 Nov 2012 |
An innovative concept has been reported for the separation of rare cells, such as prostate cancer cells or circulating tumor cells, using microfluidics.
The technique allows an entire blood draw to be processed, in continuous manner, in a shorter period of time, and does not rely on antibodies, which is important because not all cancer cells express antigens.
Scientists at the University of Cincinnati ( OH, USA), used inertial microfluidics to continuously and selectively collect rare cells, such as circulating tumor cells, based on their size versus other biomarkers. The advantage of inertial microfluidics in cell separation is that it can be done easily and without cumbersome equipment. This type of work is leading to an entirely new generation of testing capabilities that particularly lend themselves to direct use in the field and in physicians' offices in just about any country and any economic setting. Another area in which this device could be useful is in working with cell cultures.
The device is essentially a clear, plastic, flexible square that is relatively small, at about 12.7 mm across. The device contains four outlet ports that separate the blood into different streams, allowing the collection of outputs containing dilute plasma, red blood cells, and white blood cells. This quick, low-cost way of running a diagnostic test could potentially be used in a resource-limited setting. Ian Papautsky, PhD, an associate professor at the College of Engineering and Applied Science (Cincinnati, OH, USA), said, "If you have a mixture of multiple cells where some cells are small and other cells are big, we could separate these cell populations very easily. Anytime you need to separate based on size, we can do it using inertial microfluidics."
Prof. Papautsky explained, “There are a lot of clinical diagnostic tests that are based on blood. One of the most common tests that are done in a hospital is the complete blood count (CBC). Through this test, a wide range of conditions like anemia, malaria or leukemia are diagnosed. In all of these diagnostic tests, blood must be separated into its components, and that's what this device does. So, instead of using a big centrifuge to do it, we can do it with this little device." The microfluidic device allows for a diagnosis in less time in a much easier fashion. The study was reported at the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) held October 28 to November 1, 2012, in Okinawa (Japan).
Related Links:
University of Cincinnati
College of Engineering and Applied Science
microTAS
The technique allows an entire blood draw to be processed, in continuous manner, in a shorter period of time, and does not rely on antibodies, which is important because not all cancer cells express antigens.
Scientists at the University of Cincinnati ( OH, USA), used inertial microfluidics to continuously and selectively collect rare cells, such as circulating tumor cells, based on their size versus other biomarkers. The advantage of inertial microfluidics in cell separation is that it can be done easily and without cumbersome equipment. This type of work is leading to an entirely new generation of testing capabilities that particularly lend themselves to direct use in the field and in physicians' offices in just about any country and any economic setting. Another area in which this device could be useful is in working with cell cultures.
The device is essentially a clear, plastic, flexible square that is relatively small, at about 12.7 mm across. The device contains four outlet ports that separate the blood into different streams, allowing the collection of outputs containing dilute plasma, red blood cells, and white blood cells. This quick, low-cost way of running a diagnostic test could potentially be used in a resource-limited setting. Ian Papautsky, PhD, an associate professor at the College of Engineering and Applied Science (Cincinnati, OH, USA), said, "If you have a mixture of multiple cells where some cells are small and other cells are big, we could separate these cell populations very easily. Anytime you need to separate based on size, we can do it using inertial microfluidics."
Prof. Papautsky explained, “There are a lot of clinical diagnostic tests that are based on blood. One of the most common tests that are done in a hospital is the complete blood count (CBC). Through this test, a wide range of conditions like anemia, malaria or leukemia are diagnosed. In all of these diagnostic tests, blood must be separated into its components, and that's what this device does. So, instead of using a big centrifuge to do it, we can do it with this little device." The microfluidic device allows for a diagnosis in less time in a much easier fashion. The study was reported at the Sixteenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (microTAS) held October 28 to November 1, 2012, in Okinawa (Japan).
Related Links:
University of Cincinnati
College of Engineering and Applied Science
microTAS
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







